You need to be logged in to view this video
Pre-IPO Investment Opportunity: A Biotech Developing Breakthrough Medical Treatments for Heart Disease, Strokes, Parkinson's Disease, Multiple Sclerosis, and More
Released on Tuesday, August 10, 2021•BIOTECH
Zhittya Genesis Medicine, Inc., is developing novel pharmaceuticals that have the potential to treat and reverse diseases that account for more than 50% of all adult deaths, worldwide. In FDA-authorized clinical trials these drugs have shown remarkable success in reversing severe coronary artery disease and healing chronic diabetic foot ulcers. New clinical trials are planned in the coming year to treat patients with Parkinson's disease, ALS (Lou Gehrig's disease), multiple sclerosis, chronic stroke, and Alzheimer's disease. A very attractive Pre-IPO investment is now being offered to suitable investors to help fund the upcoming IPO, which has a firm commitment from a highly regarded securities firm and will take place in 5-6 months.
Jack Jacobs
Zhittya Genesis Medicine, Inc.,
President and Chief Scientific Officer
Daniel Montano
Zhittya Genesis Medicine, Inc.,
CEO
Trending Now
Filter By Category
Filter By Keywords
Loading...